To the Editor: The review by Brodaty and colleagues1 on drug treatment of Alzheimer's disease provides a good, concise and balanced overview. However, Pfizer takes issue with some of the referenced safety data.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Pfizer Pty Ltd, West Ryde, NSW.
Correspondence: Bill.Lam@Pfizer.com
- 1. Brodaty H, Ames D, Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease [review]. Med J Aust 2001; 175: 324-329.
- 2. Rogers S, Friedhoff L. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
- 3. Australian-approved Product Information for Donepezil. Sydney: Pfizer Pty Limited, 10 December 2001.
- 4. Winblad B, Engedal K, Soininen H, et al and the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezii in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
Online responses are no longer available. Please refer to our instructions for authors page for more information.